Tien-Li Lee Acquires 10,000 Shares of Aardvark Therapeutics (NASDAQ:AARD) Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Tien-Li Lee purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The shares were acquired at an average cost of $9.66 per share, with a total value of $96,600.00. Following the completion of the purchase, the chief executive officer owned 1,543,384 shares of the company’s stock, valued at $14,909,089.44. The trade was a 0.65% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Tien-Li Lee also recently made the following trade(s):

• On Friday, September 12th, Tien-Li Lee purchased 5,000 shares of Aardvark Therapeutics stock. The shares were acquired at an average cost of $8.50 per share, with a total value of $42,500.00.
• On Thursday, September 11th, Tien-Li Lee purchased 6,000 shares of Aardvark Therapeutics stock. The shares were acquired at an average cost of $7.82 per share, with a total value of $46,920.00.
• On Wednesday, September 10th, Tien-Li Lee purchased 9,000 shares of Aardvark Therapeutics stock. The shares were acquired at an average cost of $7.91 per share, with a total value of $71,190.00.

Aardvark Therapeutics Price Performance

AARD opened at $10.26 on Wednesday. The firm has a 50 day simple moving average of $10.82 and a 200 day simple moving average of $10.51. Aardvark Therapeutics, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.14).

Analysts Set New Price Targets

AARD has been the subject of several recent analyst reports. HC Wainwright initiated coverage on shares of Aardvark Therapeutics in a research note on Monday, June 30th. They issued a “buy” rating and a $40.00 target price for the company. Wall Street Zen downgraded shares of Aardvark Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. Royal Bank Of Canada lowered their target price on shares of Aardvark Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Thursday, August 14th. Finally, Bank of America lowered their target price on shares of Aardvark Therapeutics from $26.00 to $25.00 and set a “buy” rating for the company in a research note on Thursday, August 28th. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Aardvark Therapeutics presently has an average rating of “Buy” and an average target price of $32.60.

Institutional Trading of Aardvark Therapeutics

Large investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Aardvark Therapeutics in the second quarter valued at $42,000. New York State Common Retirement Fund acquired a new stake in Aardvark Therapeutics in the second quarter valued at $99,000. Bank of America Corp DE lifted its stake in Aardvark Therapeutics by 72.9% in the second quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock valued at $108,000 after acquiring an additional 3,369 shares during the last quarter. Walleye Capital LLC acquired a new stake in Aardvark Therapeutics in the first quarter valued at $88,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Aardvark Therapeutics in the first quarter valued at $153,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.